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Summal~ 
Several receptors and counter-receptor pairs on T  cells and on antigen-presenting cells (APCs) 
deliver costimulatory signals to T  cells during antigen presentation. The CD28 receptor on T 
cells with its ligand B7 represents one of the best characterized and most important examples 
of this costimulation. We show here that interleukin 12 (IL-12), a cytokine also produced by 
APCs (monocyte/macrophages and B cells) and active on T and natural killer cells, has a strong 
synergistic effect with the B7/CD28 interaction in inducing proliferation and cytokine production 
in both mitogen-activated and freshly isolated peripheral blood T cells. Together with anti-CD28 
antibodies, IL-12 induces proliferation of T cells to levels higher than those obtained with IL-2 
stimulation and it is effective at IL-12 concentrations 100-  to  1,000-fold lower than effective 
concentrations of IL-2. The proliferative effect of anti-CD28 and IL-12 is resistant to moderate 
doses of cyclosporin A and is largely independent of endogenous IL-2. IL-12, in synergy with 
anti-CD28 or B7-transfected ceils, is most effective in inducing interferon 3' (IFN-3') production, 
but production of tumor necrosis factor ot and granulocyte/macrophage  colony-stimulating factor 
is also observed. IL-12-induced IFN-3" production in peripheral blood mononuclear cells is inhibited 
by the chimeric molecule CTLA-4 immunoglobulin, which prevents binding of CD28 to B7, 
suggesting that endogenous B7 on the mononuclear cells and IL-12 cooperate in inducing IFN-3' 
production. IL-10 inhibits both IL-12 production and B7 expression on monocytes. These two 
effects are largely responsible for the ability of IL-10, acting on accessory cells, to inhibit IFN-3" 
production by lymphocytes, because anti-CD28 antibodies and IL-12 can reverse the inhibitory 
effect of IL-10 on IFN-3" production.  Our results in vitro suggest that the synergy between 
B7 and IL-12, a surface antigen and a soluble product of APCs, respectively, plays a role in regulating 
T  cell activation and immune response in the microenvironment of inflamed tissues. 
~  Cs  such  as  macrophages  and  dendritic  ceils  deliver 
costimulatory signals that are required for optimal ac- 
tivation of T lymphocytes. Several receptor counter-receptor 
pairs mediate adhesion between APC and T cells and deliver 
activating signals  to T  ceils. The interaction of B7 with its 
CD28 receptor on T  cells represents the best characterized 
example of this costimulation. Unlike surface molecules ex- 
pressed on APCs, the role of soluble cytokines produced by 
APCs in regulating the response of T  cells received less at- 
tention, although a role for IL-1 and, to some extent, for 
IL-6 and TNF-ot, has been demonstrated. IL-12 is a hetero- 
dimeric cytokine (1-3) produced by monocyte-macrophages, 
B cells, and other accessory cell types especially upon bac- 
terial stimulation (4), which has immunomodulatory effects 
on T and NK cells (1, 5-8). IL-12 induces lymphokine pro- 
duction and is especially potent in inducing production of 
IFN-7 alone or in synergy with other inducers (5); it also 
induces proliferation of activated T and NK cells (6, 9), aug- 
ments the cytotoxicity of NK cells  (1,  10),  and favors the 
generation of cytotoxic T cells and lymphokine-activated killer 
cells (11). Because IL-12 is a likely physiologic inducer of the 
generation and maturation of T helper type 1 cells (Thl) (7, 
8, 12) and, through its ability to induce IFN-3, production, 
is instrumental in activating phagocytic cells in response to 
infection (4, 13, 14), a central role for IL-12 in inflammation 
and immune response as a product of accessory cells and APCs 
is being increasingly recognized (15). However, the prolifer- 
ative effect of IL-12 on T  cells has always been reported to 
be modest in comparison to the proliferation induced by IL-2 
and restricted to a temporal window during activation of T 
cells (6, 9).  Depending on the cell type, IL-12 may display 
a modest additive effect with IL-2 in inducing proliferation 
or, as in the case of NK cells or of T  cells with TCR-3,/~, 
it may inhibit IL-2-induced proliferation (6). These findings 
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geneous receptor for IL-12, able to deliver both proliferative 
and antiproliferative signals (16, 17).  IL-12, even in associa- 
tion with IL-2, has no or an extremely low ability to induce 
proliferation in fresh resting peripheral lymphocytes (6, 9). 
However, especially in cultures of 5-6 d,  IL-12 has an en- 
hancing  effect on T  cell proliferation  induced by a variety 
of stimuli, including mitogenic lectins, allogeneic cells, anti- 
CD3 antibodies,  and phorbol diesters.  A  synergistic effect 
of IL-4 and IL-12 was reported for proliferation  of human 
CD56 + NK cells but not of human T  cells (18). Although 
in certain conditions, IL-12 can elicit low levels of IL-2, the 
neutralization  of endogenous  IL-2 in most cases  does not 
diminish the proliferation induced by IL-12 or its enhancing 
effect on the proliferation induced by other mitogenic stimuli; 
only the enhancing effect of IL-12 on phorbol diester-induced 
T ceU proliferation was inhibited by anti-IL-2 antibodies (6). 
The interaction  of the CD28 receptor,  present  on most 
T cells, with its counter-receptor B7, expressed on dendritic 
cells  and activated monocytes, B cells,  and repeatedly acti- 
vated T cells, represents an important pathway ofT cell stim- 
ulation (19, 20). Not only is a costimulus through BT/CD28 
interaction essential for optimal T  cell stimulation after in- 
teraction of the TCR with peptide antigen  in the context 
of the MHC (21, 22), but activation through this pathway 
also prevents the induction of T  cell anergy (23), observed 
in many conditions in which the TCR alone is challenged 
(24).  CD28 is a homodimeric molecule of 44-kD subunits 
expressed on most CD4 + and about half of CD8 + human 
T cells but not on NK cells (25). Antibodies against CD28 
augment the proliferation and production of cytokines by T 
cells in response to TCR or CD3 stimulation, to stimulation 
by anti-CD2 antibodies, and to phorbol diesters (21, 22, 26). 
Part of the costimulatory activity of CD28 antibodies is due 
to a cyclosporin A (CsA)l-resistant posttranscriptional mech- 
anism that results in increased stability of the IL-2 message 
(27, 28). However, anti-CD28  antibodies also have a direct 
transcriptional,  CsA-sensitive mechanism to induce IL-2 gene 
expression,  especially when  the antibodies are cross-linked 
on the cell surface or when IgM antibodies are used (29-31). 
CTLA-4 is another T  cell surface receptor, with some ho- 
mology to CD28, that binds to the counter-receptor B7 (32). 
CTLA-4Ig is a chimeric immunoglobulin C3' fusion protein 
that binds with high avidity to B7 and blocks several T ceil-de- 
pendent  immune  responses in vitro  and in vivo (32,  33). 
In this study, we investigated whether a cooperative effect 
between IL-12 and B7, a soluble and surface-bound product 
of APCs,  respectively, may be required  for optimal  T  ceil 
activation. Our results show that the B7/CD28 stimulatory 
pathway  synergizes  with  IL-12 in  inducing  both  efficient 
proliferation  and cytokine production  in human  T  cells. 
1 Abbreviations used in this paper: CHO,  Chinese hamster ovary; CsA, 
cyclosporin A; TPA, 12-O-tetradeanoylphorbol 13-acetate. 
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Materials  and Methods 
Cytokines and Reagents.  Chinese hamster ovary (CHO) cell-de- 
rived rNKSF/IL-12 was provided by Dr. S. Wolf (Genetics Insti- 
tute,  Boston,  MA);  recombinant  IL-2 (107 U/rag) was provided 
by the Division of Cancer Treatment (National Cancer Institute, 
Bethesda, MD); and CHO cell-derived hill0 (1.5 x  107 U/rag), 
by Dr. K. Moore (DNAX Research Institute, Palo Alto, CA). The 
following reagents were obtained from commercial sources: PHA 
(Sigma Chemical Co.,  St. Louis, MO); heat-fixed Staphylococcus 
aureus Cowan strain 1 (Pansorbin; Calbiochem-Behring Corp., La 
Jolla,  CA);  12-O-tetradecanoylphorbol  13-acetate (TPA; Sigma 
Chemical Co.); CsA (Sandoz Forschungsinstitut  GmbH, Vienna, 
Austria). 
Antibodies.  mAb  OKT3-  (IgG2a,  anti-CD3)  and  OKM1- 
(IgG2b, anti-CDllb) producing  ceils were obtained from Amer- 
ican Type Culture Collection, Rockville, MD); CK248 (IgM, anti- 
CD28) (22) and 93 (IgG1, anti-CD25)  were kindly provided by 
Dr. Lorenzo Moretta (Istituto Nazionale per la Ricerca sul Cancro, 
Genova, Italy); 1.12 (IgG2a, anti-HLA-DR) were provided by Dr. 
goberto Accolla (University of Verona, Verona, Italy); and B52.1 
(IgM, anti-CD14) (34) was produced in our laboratory. The mAb 
9.3 (IgG2a, anti-CD28)  (35) was donated by Dr. J. Hansen (Fred 
Hutchinson Cancer Center, Seattle, WA); mAb B7.4 (IgG, anti- 
B7) and mAb CD28.1,  CD28.2, CD28.3, CD28.5, 15E8 (IgG1, 
anti-CD28)  (31) were obtained  through participation  in the 5th 
International Conference on Human Leucocyte Differentiation An- 
tigens, Boston, MA, Nov. 3-7, 1993. The specificity  of all the anti- 
CD28 antibodies used was assigned at the Conference Workshop 
and confirmed in our laboratory by reactivity in immunofluores- 
cence with CD28-transfected J32 cell line, but not with the CD28- 
negative parental cell lines. In immunofluorescence, mAb 9.3 in- 
hibits the binding of mAb CD248 to CD28 + T cells. Anti-IL-2 
polyclonal goat antiserum was prepared in our laboratory and, at 
1:200 dilution,  completely neutralizes the activity of I>100 U/ml 
of 1I.,2. CTLA-4Ig  (32) and B7-transfected CHO cells (36) were 
kindly provided by Dr. Peter S. Linsley (Bristol-Meyers  Squibb Phar- 
maceutical Research Institute, Seattle, WA); B7-transfected L cells 
(37) by Dr.  Lewis Lanier (DNAX Research Institute). 
Cytokine Assays.  RIAs for human IFN-3' and human TNF-c~ 
were performed as described (38, 39) using mAbs B133.1/B133.5 
and B154.9/B154.7, respectively.  GM-CSF was measured by a newly 
developed double determinant  RIA using  antibody C9.1 bound 
to plastic as the capture antibody and antibody C16.3 as the 12sI- 
labeled detection antibody according to the same protocol previ- 
ously described for IFN-3/and TNF-oe RIAs (38, 39). Recombinant 
cytokines were used to standardize all assays. 
Preparation of Human PBMC.  Peripheral blood obtained from 
healthy donors was anticoagulated with heparin. PBMC were sepa- 
rated on Ficoll-Hypaque (Lymphoprep; Nyegaard and Co., Oslo, 
Norway) density gradient,  and lymphocytes (PBL) were obtained 
after adherence of PBMC to plastic flasks (1 h, 37~  In some 
experiments, purified preparations of small high density lympho- 
cytes were purified on a discontinuous Percoll gradient (40). These 
preparations were devoid of  cycling ceils, as determined by propidium 
iodide staining and flow cytometry analysis, and did not express 
significant levels of activation markers CD25, CD69, CD71, and 
4F2. Approximately  two thirds  of the CD4 § cells contained in 
these populations  were CD45 RA +,  a phenotype  attributed  to 
naive T cells. PHA-blasts (>98% activated T cells), as determined 
by indirect  immunofluorescence  with antileukocyte  subset anti- 
bodies, were obtained after a 5-d culture of PBL in the presence 
of 5 #g/ml of PHA (5, 41). Cells were cultured in 200 #1 RPMI 
1640 medium supplemented with 10% heat-inactivated FCS (Ir- vine Scientific, Santa Ana, CA) in 96-weU round-bottomed plates 
(Flow Laboratories Inc., McLean, VA) with 0.2  x  l& cells/weU 
for proliferation and 106 cells/well for cytokine production. For 
detection of thymidine ([3H]TdR.) uptake, 1 #Ci/well of [3H]TdR 
was added to the wells in the last 6 h ofcuhure; ceUs were collected 
on a glass filter and radioactivity measured. All cultures were per- 
formed in triplicate. 
Immunofluorescence  Assay.  This was performed as described (42). 
Briefly, cells were sequentially incubated (30  rain,  4~  with 
saturating  concentrations of antibodies in  PBS containing  1% 
gelatin, 1% human plasma, and 0.1% NAN3, washed three times, 
and incubated with FITC-conjugated goat F(ab')~ anti-mouse Ig 
(absorbed to human IgG-Sepharose before use; Cappel Laborato- 
ries, Cochranville, PA), washed again, and analyzed for fluores- 
cence and light scatter using an Ortho Cytofluorograf 50H con- 
nected to  a 2100 Data  Handling  System (Ortho  Instruments, 
Westwood, MA). 
Results 
IL-12  Synergizes  with  Anti-CD28  Antibodies  in  Inducing 
Proliferation of PHA Activated  and Freshly Isolated Pe@heral 
Blood Human T Cells.  IL-12 has a minimal proliferative effect 
on resting PBL, whereas a dose-dependent proliferation is 
induced by IL-12 on PHA-activated T cell blasts or on acti- 
vated NK cells (6, 9). Maximal proliferation induced by IL-12 
on activated T ceils is, however,  always lower than that in- 
duced by IL-2 (6, 9). Furthermore, maximal responsiveness 
to IL-12, unlike that to  IL-2,  is  restricted to  *2-3  d  of 
stimulation with PHA, perhaps reflecting a more transient 
expression  of the IL-12 receptor compared with the IL-2 
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Figure  1.  Anti-eD28 antibody  CK248 synergizes  with II.-12 and Ib2 
in inducing  proliferation  of PHA-blasts. PHA-blasts were obtained  after 
5 d culture of PBL in the presence of 5 #g/ml PHA and incubated for 
3 or 6 d with the indicated  concentrations  of II.~12 (solid  symbols) or IL-2 
(open symbols) and no antibodies (O, O) or 0.04%o (V, ~7), 0.2% (A, 
A) or 1% (11, I7) ascites containing  antibody  CK248. [3H]TdR.  uptake 
was evaluated  after a 6-h pulse at the end of the culture period. Results 
are average of values obtained with PHA-blasts from three donors. 
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receptor (17). The PHA-activated blast cell preparations used 
in the preset studies were collected 5 d after PHA stimula- 
tion in order to avoid the background proliferation observed 
in PHA-induced cells collected at an earlier time of culture. 
As shown in Fig. 1, increasing concentrations of IL-12 in- 
duced modest proliferation, as measured by [3H]TdR uptake, 
in PHA-blasts both at days 3 and 6 of culture, whereas IL-2 
alone induced efficient proliferation, with a maximum effect 
observed around 10 ng/ml. The anti-CD28 antibody CK248, 
in the absence of IL-12 or IL-2, induced proliferation at day 
3 when used at a concentration of ascites fluid of 1:500 or 
higher. Proliferation at day 6 was lower. Addition of anti- 
body CK248 induced a modest synergistic enhancement of 
IL-2-induced proliferation but a strong synergistic enhance- 
ment of IL-12-induced proliferation. IL-12 in the presence 
of CK248 was effective at concentrations as low as 5 pg/ml 
and induced equivalent [3H]TdR uptake at concentrations 
2-3 orders of magnitude lower than those required with IL-2. 
Antibody CK248 was found to induce a proliferative effect 
only early in the culture, whereas the modest proliferation 
induced with IL-12  was observed from 1 to 6  d  and the 
proliferation induced by IL-2, CK248 and IL-2, or CK248 
and IL-12 was maximum at day 6 (Fig.  2) and declined at 
later times (not shown). When anti-CD28 antibodies with 
distinct binding properties were tested for their ability to 
induce PHA blast proliferation in conjunction with IL-12, 
it was observed that mAb 9.3, CD28.2,  and 15E8,  which 
in the presence of  phorbol diesters have been reported to induce 
IL-2 production by the Jurkat cell line, synergize with IL-12, 
although less efficiently than CK248. mAb CD28.1, CD28.3, 
and CD28.5, which have been reported not to induce Ca  2+ 
flux or IL-2 production in Jurkat cells (31), failed to syner- 
gize with IL-12 (Table 1). CK248 was the only antibody to 
induce consistent levels of proliferation in PHA blasts in the 
absence of IL-12; this result parallels the reported ability of 
CK248 to induce IL-2 production by Jurkat cells in the ab- 
sence of phorbol diester (31). Indeed, in the presence of the 
phorbol diester TPA, mAb 9.3 was shown to be as efficient 
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Figure  2.  Kinetics  of proliferation  of PHA blasts in response to IL-2, 
II.-12, and anti-CD28 antibodies.  PHA-blasts  were  incubated  with the anti- 
CD28 antibody  CK248 (ascites  1%o), IL-2  (100 ng/ml),  or Ib12 (0.5 ng/ml) 
and [3tt]TdR  uptake  was evaluated  at 1, 2, 3, 4, and 6 d after a 6-h pulse. 
Results are average of values obtained with three donors. Table  1.  Proliferation and IFN-'T Production of PHA Blasts Stimulated  by Anti-CD28 Antibodies  in the Presence or Absence of IL-I2 
[3H]TdR uptake, cpm  IFN-% U/ml 
mAb*  no IL-12  IL-12,  1 ng/m]  no IL-12  II~12,  1 ng/ml 
Medium  4,988  24,579  5  37 
CK248  43,391  71,978  85  1,042 
9.3  8,753  42,423  7  184 
CD28.1  5,199  25,866  7  86 
CD28.2  7,740  42,276  8  405 
CD28.3  4,601  25,548  6  96 
CD28.5  6,177  28,563  7  155 
15E8  12,660  56,518  11  717 
* PHA blasts were cultured in the presence or absence of I  ng/ml IL-12 in the presence of ascites (0.5%)  containing the indicated mAb. 9.3 mAb 
was used at 10/~g/ml. IFN-3, was measured in the cell free supernatant  fluid collected after 18-h stimulation and [3]TdK uptake was measured after 
a 6-h pulse at day 3 of stimulation. 
as CK248 in synergizing with IL-12 in inducing PHA blasts 
proliferation (results not shown). A synergistic proliferative 
effect with IL-12 was observed by stimulating PHA blasts 
with L cells transfected with the CD28-1igand B7, but not 
with nontransfected cells (Fig.  3). 
We tested the ability of anti-CD28 antibody CK248 to 
synergize with IL-2 and IL-12 in inducing proliferation of 
freshly isolated PBL (not shown). Synergistic effect with IL-12 
was observed at day 6, but not at day 3, although a modest 
enhancement of IL-2-induced proliferation was already ob- 
served at day 3. A similar kinetics of proliferation, with max- 
imum [3H]TdR uptake at day 6, was also induced by mAb 
CD248 and IL-12 in two experiments using PercoU-separated 
high density small lymphocytes (results  not shown). 
We analyzed  the role of endogenous IL-2 in the syner- 
gistic effect between IL-12 and anti-CD28 antibodies by using 
neutralizing anti-IL-2 and anti-IL-2 receptor antibodies. Be- 
cause CsA has been demonstrated to differentially affect the 
different pathway by which CD28 signal transduction affect 
IL-2 gene expression,  we also analyzed  the ability of CsA 
to inhibit this synergy. The results are shown in Fig. 4. The 
proliferative  effect induced by anti-CD28 alone was almost 
completely inhibited both by blocking endogenous IL-2 (with 
a mixture of a goat anti-human IL-2 antibody and an anti- 
CD25 mAb; referred to in Fig. 4 and in this section as anti- 
IL-2) or by adding CsA (20 ng/ml). In both conditions, a 
similar but less complete inhibition of proliferation induced 
by plastic-bound anti-CD3 mAb was observed, whereas the 
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Figure 3.  B7-transfected L calls synergize with 
IL-12 in inducing  proliferation of PHA blasts. PHA 
blasts were incubated with anti-CD28 antibody 
CD248 (ascites 0.2%) or with different numbers 
of L cells transfected or not with the B7 antigen 
in  the  presence or  not  of  II-12  (1  ng/ml). 
[3H]TdR. uptake (cpm) was evaluated at 3 d after 
a 6-h pulse. Results are from one experiment rep- 
resentative of three performed. 60000- 
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Figure 4.  Effect of CsA and inhibition of 
endogenous  IL-2 on PHA-blast  proliferation. 
PHA-blasts were incubated  for 3 d in culture 
medium in the presence of anti-CD28 anti- 
bodies  (1%  ascites fluid  containing  CK248 
mAb),  IL-12 (1  ng/ml),  solid-phase  bound 
anti-CD30KT3 antibody (5 #g/ml) or their 
combination.  CsA  was  used  at  20  ng/ml, 
anti-IL-2 was a mixture of goat anti-human 
IL-2 serum  (1:200) and  anti-CD25  mAb 93 
(ascites 1:100). [3H]TdR uptake was measured 
by scintillation  counting after a 6-h pulse at 
the end of the culture time. Results are mean 
_+  of four experiments. 
low proliferation induced by IL-12 was largely unaffected by 
either anti-IL-2 or CsA. The proliferation induced by anti- 
CD3 and anti-CD28 mAb together was largely unaffected 
by CsA or anti-IL-2, although the effect of each antibody 
alone was inhibited by CsA and required endogenous IL-2 
activity. Unexpectedly, CsA significantly inhibited prolifera- 
tion induced by anti-CD3 and anti-CD28 antibodies when 
the IL-2 activity was neutralized. The proliferation induced 
by the synergistic effect of anti-CD28 and IL-12 was unaffected 
by CsA and only partially dependent on endogenous IL-2. 
Unlike the synergistic effect of anti-CD28 and IL-12, the en- 
hanced proliferation in response to IL-12 induced by anti- 
CD3 mAb was still partially affected by CsA. When higher 
concentrations of CSA were used (>t200 ng/ml),  a more 
generalized  inhibition of proliferation was observed. 
IL-12 Synergizes with Stimulation  of CD28 by Antibodies or 
by Its Ligand B7 in Inducing Cytokines in T Cells.  IL-12 syn- 
ergizes with the anti-CD28 antibody CK248 or with B7- 
transfected CHO cells in inducing production of IFN-3, from 
PHA-blasts (Fig.  5). Control parental CHO cells (Fig.  5) 
or control ascites (not shown) had no significant effect. Iden- 
tical results were obtained with B7-transfected  L cells (not 
shown). The anti-CD28 IgG2a mAb 9.3, unlike the IgM 
mAb CK248, did not induce IFN-y production by itself, 
and enhanced IFN-3' production induced by IL-12 only two- 
fold on average (Table 2).  mAb 9.3,  which competes for 
binding to the CD28 antigen on T  cells (not shown), in- 
hibited the induction of IFN-3' and the synergy with IL-12 
of CK248 (Table 2). Two other anti-CD28 mAb synergized 
with IL-12 in inducing IFN-3, production from PHA-blasts 
(CD28.2 and 15E8) whereas three mAbs (CD28.1, CD28.3, 
and CD28.5) showed only minor effects (Table 1). The ability 
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Figure  5.  Anti-CD28 antibody CK248 and B7-transfected CHO-cells 
synergize with 1I.-12 in inducing IFN-'y production from PHA-blasts. PHA 
blasts were cultured for 18 h in the presence of medium or increasing con- 
centrations  of IL-12, and the indicated dilutions of ascites containing the 
anti-CD28  mAb CK248, parental CHO cells or B7-transfected CHO cells 
at the PHA-blast  CHO-cell ratios indicated.  At the end of the culture, 
cell-free  supematant fluids were collected and IFNo, assayed by RIA. Results 
are mean  _+  SE of four experiments. 
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IFN-3, (Mean _+ SE) 
Antibodies:~  Medium*  IL-2  IL-12  IL-2  +  IL-12 
U/ml 
PX63  1_+ 0  20 +  9  35 + 4  515 +  29 
9.3  1 _+ 1  23 +  10  70 _+ 45  477 _+ 122 
CK248  69 + 34  132 +  57  1,075 _+ 96  1,190 +  71 
CK248  +  9.3  1 +  1  37 _+ 23  77 _+ 29  633 + 68 
* PHA-blasts  were cultured for 18 h in the presence of the following inducers:  medium; IL-2 (10 ng/ml); 1I.-12 (1 ng/ml); or a combination of the 
two cytokines.  IFN-'y was assayed in the cell-free supernatant  fluid by RIA. Results  are mean  +  SE from four experiments. 
~t Antibodies PX63 (irrelevant IgG1) and CK248 (anti-CD28) were added as a 1% dilution of ascites fluid; antibody 9.3 (anti-CD28) was added at 10 #g/ml. 
of the different anti-CD28 mAb to synergize with IL-12 in 
inducing  IFN-q/parallels their ability to enhance IL-12-in- 
duced proliferation (Table 1). As for IL-2 induction in Jurkat 
cells (31) or proliferation  of PHA blasts (Table  1),  CK248 
was the only antibody to induce significant IFN-3' produc- 
tion in the absence of IL-12. Although mAb 9.3 alone was 
relatively inefficient in synergizing with IL-12,  when used 
in combination with the phorbol diester TPA and IL-12, this 
mAb induced similar levels of IFN-'y production as observed 
with  CK248  and IL-12  (results not  shown). 
Anti-CD28  mAb CK248 and B7-transfected CHO cells 
induced the production by PHA blasts not only of IFN-% 
but also of TNF-ot and GM-CSF, and this effect was enhanced 
by costimulation with IL-12 or plastic-bound anti-CD3 mAb, 
and, to a lesser extent by IL-2 (Fig.  6). However, IL-12 was 
particularly  effective in  stimulating  IFN-3'  production  as 
indicated by the fact that anti-CD28 mAb or B7-CHO in- 
duced  maximal  IFN-3'  production  when  in  combination 
with IL-12,  whereas  they  induced  TNF-c~  and  GM-CSF 
more efficiently when  combined  with  plastic-bound  anti- 
CD3.  A  strong  synergy of IL-12  with  IL-2 or anti-CD3 
was also observed in  the induction  of IFN-7 production, 
but not of TNF-ot or GM-CSF (Fig.  6). 
mAb CK248 also synergized with IL-12 in inducing IFN-3" 
but not TNF-cr  production by freshly isolated PBL (Table 
3). The limited ability of IL-12 to induce TNF-ot produc- 
tion was underscored by the fact that  in the same cultures 
in which IL-12 failed to enhance the TNF-ot production in- 
duced by CK248,  the phorbol diester TPA had a dramatic 
synergistic effect in combination with CK248 (Table 3). Al- 
though the PBL preparations used in these experiments were 
depleted of adherent cells, they were not monocyte-free; how- 
ever, because IL-12 and anti-CD28 are specific stimuli for T 
(and,  in the case of IL-12,  NK) cells,  it is likely that most 
of the TNF-ot measured in these cultures was produced by 
lymphocytes. 
To analyze whether the B7-CD28 interaction plays a role 
in the IL-12-induced IFN-q/production by PBMC, we tested 
the ability of the chimeric  recombinant  soluble B7-1igand 
CTLA-4Ig to inhibit IFN-7 production (Fig. 7). CTLA-4Ig 
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Figure  6.  Anti-CD28 antibody CK248 and B7-transfected CHO cells 
augment cytokine production by PHA-blasts  in response to various in- 
ducers. PHA-blasts were cultured for 18 h in medium or in the presence 
of anti-CD28 mAb CK248 (ascites 1:100), parental  CHO cells, or B7- 
transfected CHO cells (ratio PHA-blast/CHO cells, 10:1). As indicated 
by the differently  shaded columns,  cultures  were also stimulated  in the 
presence of IIA2 (1 ng/ml), Ib2 (100 ng/ml), or plastic bound anti-CD3 
OKT3 mAb (5/~g/ml). For comparison, combinations of these three stimuli 
with Ib12 and IL-2 (final concentrations,  was  1 ng/ml and  100 ng/ml, 
respectively) are shown in the two rightmost groups  of bars. At the end 
of the 18-h culture, cell-free supernatant  fluids were collected and IFN-"/, 
TNF-c~, and GM-CSF measured by RIA. Resuhs are mean +  SE of three 
experiments. 
216  Synergy of IL-12 and B7/CD28 Table  3.  Induction of Cytokine Production in Fresh 
PBL  by IL-2,  IL-12,  or TPA  in  Combination 
with Anti-CD28  mAb  CK248 
Stimuli  CK248  IFN-3,  TNF-a 
U/ml  pg/ml 
Medium  -  2  +_  0  9  +  5 
+  41  _+  13  196  _+  103 
IL-2  -  9  _+  4  10  +  5 
+  124  _+  36  197  +  57 
IL-12  -  11  •  4  11  •  6 
+  298  _+  77  156  _+  33 
IL-2  +  IL-12  -  85  +_  26  18  +  10 
+  539  +  96  273  +  71 
TPA  -  11  +  6  119  •  44 
+  263  +  69  960  •  182 
PBL were cultured for 18 h in the presence or absence of the indicated 
stimuli and anti-CK248 mAb (ascites 1:100). IL-2 (10 ng/ml), IL-12 (1 
ng/ml),  or TPA  (1.6  x  10-s  M)  were  used to  stimulate  cytokine 
production.  IFN-y and TNF-c~ were measured by ILIA in the cell-free 
supernatant fluid at the end of the culture. ILesults are mean  +  SE from 
nine experiments. 
duction by monocytes stimulated by various inducers,  e.g., 
S. aureus,  and that IL-10 ability to suppress IFN-'y produc- 
tion in T  and NK cells is largely due to inhibition  of IL-12 
production from accessory cells (43). However, because IL-10 
also partially inhibits IL-12-induced IFN-'y production, other 
IL-10-mediated  effects  including  inhibition  of IL-113  and 
TNF-ot production (44, 45), and also possibly inhibition  of 
expression of surface-bound stimulatory molecules (46) were 
suggested to play a role in the inhibition  of IFN-~/produc- 
tion (43).  In the experiments presented here (Fig.  8), IL-10 
reduced IFN-y production induced by IL-12 by approximately 
one  half,  confirming  the  previously reported  results  (43), 
and had no effect on IFN-'y production induced by anti-CD28 
or by the synergistic effect of anti-CD28 and IL-12 (Fig. 8). 
IFN-'y production induced by S. aureus  or by the combina- 
tion of anti-CD28  and S. aureus  was almost completely in- 
hibited by IL-IO, whereas IL-IO only partially affected IFN-qr 
induced  by anti-CD28  and  S.  aureus  when  IL-12 was  also 
added (Fig. 8). Because the data obtained from the CTLA-4Ig 
inhibition  experiments  suggested  a  role for the  B7/CD28 
interaction in IL-12-mediated induction of IFN-3' in PBMC, 
we tested whether IL-10 affects monocyte expression of B7 
antigens.  As  shown  in  Fig.  9,  incubation  of PBMC  with 
IL-10 induced a severalfold decrease of both the constitutive 
expression  and  the  IFN-3,-enhanced  expression  of B7  and 
HLA-DR  antigens on monocytes,  whereas it had no effect 
on the expression of CD14 or CDllb  antigens.  These data 
efficiently inhibited the production of IFN-3~ in PBMC prepa- 
rations stimulated with  IL-12 at the same concentration  at 
which it inhibited the enhancing effect of B7-CHO cells on 
IFN-3' production  by PHA-blasts,  stimulated  or not  with 
IL-12. Equivalent concentrations of normal human IgG had 
no  effect on  IFN-3' production. 
Effect of IL-IO  on  IFN-'x Production  and B7 Expression  in 
PBMC Stimulated in the Presence of Anti-CD28 Antibodies and 
IL-12.  We previously showed that IL-10 inhibits IL-12 pro- 
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Figure  7.  CTLA-4Ig inhibits IFN-3~  production in PBMC or in PHA- 
blasts stimulated in the presence  of B7-transfected  CHO cells. PBL or PHA- 
blasts were cultured for 18 h in medium or in the presence of the indicated 
concentrations of the chimeric protein CTLA-4Ig, and stimulated with 
the indicated combination of IL-12 (1 ng/ml) or B7-transfected CHO cells 
(PHA-blast/CHO cell ratio, 10:1). At the end of the culture, cell-free su- 
pernatant fluid was collected and IFN-3, assayed by ILIA. Representative 
experiment out of four performed. 
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Figure  8.  Ability of II.r10 (100 U/ml) to inhibit IFN-'y production by 
PBMC in response to S. aureus (1:10,000 vol/vol final dilution), anti-CD28 
mAb CK248 (ascites, final dilution 1:100), or a mixture of anti-CD28 
mAb and S. aureus, in the presence or absence of IL-12 (1 ng/ml).  PHA- 
blasts were cultured for 18 h in the presence of the indicated combination 
of cytokines or antibodies. At the end of the culture period, cell-free su- 
pernatant fluids were collected and IFN-3, was assayed by ILIA. Results 
are mean _+ SE of six experiments. Percent inhibition of IFN-'y produc- 
tion is given. 
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Figure 9.  IL-10  inhibits constitutive and IFN-q,-induced expression of 
B7 and HLA-DR on cultured human monocytes, but not expression of 
CDIlb and CD14 antigens. PBMC were cultured for 18 h in the presence 
or not of 1I.-10 (100 U/ml) and/or IFN-3' (1,000 U/ml). At the end of 
the culture, PBMC were collected, washed, and analyzed by indirect im- 
munofluorescence (flow cytometry), gating on cells with light scatter char- 
acteristics of monocytes, for the expression of CDI4 (mAb B52.1), Cllb 
(mAb OKM1), HLA-DR (mAb 1.12), and B7 (mAb B7.4). Graphs in 
the left column are PBMC cultured  without IFN-"/,  and in the right 
column, in the presence of IFN-% Dotted lines indicate control negative 
staining in the absence of a primary antibody in PBMC cultured without 
IL-10 (PBMC cultured with 1I.-10 or stained in the presence of irrelevant 
isotype control antibodies gave similar background staining); continuous 
lines indicate antibody staining of cells cultured in the absence of IL-10; 
broken lines indicate antibody staining of cells cultured in the presence 
of IL-10. Representative experiment  out of six performed. 
are consistent  with the hypothesis that inhibition of IL-12 
production and inhibition of B7 expression on accessory cells 
both have a role in the inhibition of IFN-3r production medi- 
ated by IL-10. 
Discussion 
IL-12 is considered to be a major factor for the generation 
and activation of Thl cells as well as for the generation of 
cytotoxic CD8 + T  cells and NK cells (8,  15). Unlike the 
modest proliferative  effects on IL-12  reported until now, 
our results demonstrate that in the presence of an appropriate 
costimulus, i.e., signaling through the CD28 receptor induced 
by B7-transfected cells or certain anti-CD28 antibodies, IL-12 
can induce powerful and prolonged proliferation in activated 
T  cells. No only were the maximal levels of proliferation 
obtained  with IL-12 higher than  those induced by IL-2, 
but IL-12 was  maximally effective at concentrations 100- 
to 1,000-fold lower than effective concentrations of IL-2. 
Moreover, the synergistic proliferation induced by IL-12 and 
anti-CD28 antibody was also observed with freshly isolated 
PBL. On both freshly isolated PBL or activated PHA-blasts, 
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anti-CD28 antibodies or B7-transfected cells also synergized 
with IL-12 in inducing cytokine production. 
As with previously reported data on IL-12-induced T cell 
proliferation,  it is difficult to interpret the mechanism un- 
derlying the proliferative interactions of IL-12 with T cells 
without knowledge of the characteristics and control of ex- 
pression of the IL-12 receptor. The reported affinity of 200-600 
pM for the IL-12 receptor identified by IL-12-binding assay 
(16) is difficult to reconcile with the proliferative effect of 
IL-12 described here at concentrations <0.1 pM. To further 
examine the mechanism by which anti-CD28 and IL-12 exert 
their synergistic effect, we tested the participation of endog- 
enous IL-2 and the inhibitory effect of CsA on the prolifera- 
tive response induced by this type of stimulation.  The low 
level of proliferation  induced by IL-12 was not affected by 
low doses (20 ng/ml) of CsA and was IL-2  independent, 
whereas  the proliferation  induced by the IgM anti-CD28 
mAb CK248 was completely abolished by either CsA or by 
neutralization  of endogenous IL-2.  These  results  suggest 
that the IgM antibody, like the cross-linked IgG anti-CD28 
on Jurkat cells (29, 31, 47),  induces IL-2 production by a 
CsA-sensitive mechanism. However, the synergistic effect of 
anti-CD28 plus IL-12 on proliferation was insensitive to CsA 
and only partially dependent on endogenous IL-2, suggesting 
that the biochemical signaling pathway by which anti-CD28 
synergizes with IL-12 is  different  from that by which it 
directly induces IL-2-driven proliferation. As expected from 
published results (28), CsA did not inhibit the proliferation 
induced in  T  cells by the combination of anti-CD3  and 
anti-CD28,  two stimuli that separately are CsA sensitive. It 
is also of interest that the proliferation induced by anti-CD3 
and IL-12 was still sensitive to inhibition by CsA, suggesting 
that both the direct proliferative effect of anti-CD3 and its 
cooperative  effect with  IL-12 are mediated  by a possibly 
common, CsA-sensitive signal transduction mechanism. 
The  synergistic  effect  of the  B7/CD28  costimulatory 
pathway with IL-12 was observed not only for the prolifera- 
tion of T cells, but also for the production of cytokines, par- 
ticularly  IFN-%  The combination of anti-CD28  or B7- 
transfected cells with IL-12 is the most efficient condition 
for stimulation of IFN-3, production in freshly isolated or 
lectin-activated T cells yet described. Other cytokines such 
as TNF-ol and GM-CSF were also induced by a combination 
of IL-12 and CD28 receptor stimulation, but in this case, 
other stimuli such as anti-CD3 or TPA were more effective 
than IL-12 in synergizing with CD28 stimulation. These data 
show that IL-12, although able to induce low level produc- 
tion of various cytokines, is particularly efficient in inducing 
IFN-3/production, especially  when used in synergy with other 
stimuli. This is consistent with previous findings that many 
of the physiologic effects of IL-12 in vivo depend on its ability 
to induce IFN-3/(13,  14, 48). 
Whereas the IgM antibody CK248 was very efficient in 
synergizing with IL-12 in inducing IFN-3~ production and 
T cell  proliferation, the IgG2a antibody 9.3 was only moder- 
ately effective. The specificity of the effect of CK248 was, 
however, suggested by the fact that antibody 9.3, which is 
able to compete with CD248 for binding to T cells, inhibits the IFN-3,-inducing effect of CK248,  alone or with IL-12. 
The fact that CK248  has more dramatic effects on T  cells 
than do other IgG anti-CD28  antibodies and, unlike the IgG 
antibodies, induces IL-2 production and proliferation by it- 
self, has been reported (31). Cross-linking of  the IgG2a mAb 
9.3 on the Jurkat T cell line induces IL-2 production by a 
CsA-sensitive mechanism (47). In light of our findings that 
the ability of CK248 to induce T cell proliferation and pre- 
sumably IL-2 production is CsA-sensitive, it is possible that 
the IgM mAb CK248 induces a biologic response similar to 
that of cross-linked IgG antibodies. Using several  anti-CD28 
antibodies  with different binding characteristics, we have 
shown that the synergistic effect with IL-12 for both prolifer- 
ation and IFN-'y production is observed only with those an- 
tibodies that induce efficient Ca  2§  flux and, in the presence 
of phorbol diester, IL-2 production in Jurkat cells (31). Three 
anti-CD28 antibodies that have been previously reported to 
be  inefficient  in  both  functions (31) also failed to  show 
significant synergism with IL-12. mAb CK248 stands alone 
in this as in a previous study (31) from its ability to induce 
by itself IL-2 production in Jurkat cells and low but significant 
proliferation and IFN-3~ production in human T cells. As dis- 
cussed above, this unique property of CK248 may depend 
on its IgM isotype, which may induce cross-linking of CD28, 
possibly a sufficient signal for IL-2 production (47). Indeed, 
CK248 synergistic effects with IL-12 are very similar to those 
observed when the IgG2a  mAb 9.3 is used together with 
the phorbol diester TPA. The sensitivity of the direct effect 
of CK248 to CsA and its dependence to IL-12 compared with 
the resistance to CsA of its synergistic effect with IL-12 sug- 
gests that different mechanisms are responsible for the direct 
proliferative effect and the synergism with IL-12. Because 
the synergistic effects of CD28 stimulation with IL-12 are 
also observed using the physiologic CD28 ligand B7, it is 
likely that the response observed with CD248 and other anti- 
CD28 mAb in the presence of IL-12 reflects the physiologic 
response of activation of the B7/CD28 costimulatory pathway. 
Our results with human T cells suggest that optimal CD28 
stimulation in combination with IL-12 drives proliferation 
and cytokine production by a mechanism that is largely in- 
dependent of IL-2 production. Although proliferation induced 
by anti-CD28 and IL-12 was more efficient and was observed 
earlier with preactivated PHA blasts than with PBL, produc- 
tion of IFN-3' was similarly induced in both cell types. It 
should, however, be considered that NK cells, present in PBL 
preparations,  are responsible for a proportion of the IFN-3' 
produced in response to IL-12 stimulation (41). Although 
we could not demonstrate any effect  of mAb CK248 on IFN-y 
production by purified NK cells (not shown), it can not be 
excluded that NK cells might be activated by factors pro- 
duced by T cells activated by anti-CD28 and IL-12 and that 
might amplify the IFN-3, production observed using total 
PBL. The results with human PBL contrast with those ob- 
tained with mouse naive T cells in which we did not observe 
a responsiveness to IL-12, even  when the cells were costimu- 
lated by specific antigen and B7 (37). These results may be 
explained by the presence among PBL of a proportion of 
memory  T cells, which might have  been rendered responsive 
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to IL-12 by previous exposure to antigen. The kinetics of 
proliferation of fleshly purified PBL, with maximal prolifer- 
ation observed  at day 6, suggests the possibility that nonspecific 
stimuli related to the culture conditions  and possibly, but 
not necessarily, acting through the TCR, activate a propor- 
tion of T cells to respond to CD28 and IL-12 stimulation. 
The kinetics  of proliferation  observed in this condition is 
reminiscent of that observed with stimulation with PHA and 
IL-12 (1) that is interpreted as due to activation by PHA of 
IL-12 receptors in a conformation required for induction of 
proliferation (17). Whether CD28 stimulation directly renders 
naive and memory freshly isolated peripheral blood T cells 
responsive  to IL-12, or whether a nonspecific, possibly TCR- 
dependent stimulus, is required for induction of responsive- 
ness to the proliferative response to CD28 and IL-12 stimu- 
lation,  remains to be determined. 
CTLA-4Ig inhibited the production of IFN-3' more than 
fivefold in PBMC stimulated with IL-12 alone, suggesting 
that interaction of T  cells with B7 expressed on accessory 
cells in PBMC has an important role in the responsiveness 
of flesh peripheral blood cells to IL-12. We previously showed 
that accessory cells (nonmonocytic, non-B, HLA-DR-posi- 
tive), possibly dendritic cell-like, were necessary for optimal 
IFN-3' production by resting PBL (41) but not for enhance- 
ment of the cytotoxic effect of NK cells (CD28-negative) (49). 
Although these accessory cells might be required for IFN-y 
production because of their constitutive expression of B7 an- 
tigen, we also observed low level expression of B7, at least 
at the end of an  18-h incubation period, on monocytes. 
IL-10 (43) inhibits  IL-12 production by human PBMC, 
and we have shown that the ability of IL-10 to inhibit IFN-y 
production induced by a variety of stimuli,  e.g.,  S.  aureus, 
is largely dependent on the inhibition of IL-12 production 
from accessory cells and not on a direct effect on T cells (43). 
However, because IL-10 also partially inhibited the IFN-3' 
production induced by IL-12 itself,  it  was clear that  the 
IL-10-mediated inhibition of IFN-3' production was not due 
uniquely to inhibition of IL-12 production by accessory  cells. 
We identified TNF-ot and IL-1/~ as two other accessory  factors 
that cooperate with IL-12 in inducing IFN-y production and 
proposed that downmodulation of accessory cell surface mol- 
ecules might also be involved (43). In the mouse, IL-10 was 
recently shown to prevent IFN-~/-induced  upregulation of 
B7 on macrophages but not on dendritic cells (50). We ob- 
served that, IL-10 efficiently prevented not only IFN-y-in- 
duced upregulation orB7, but also inhibited the constitutive 
expression of B7 observed in the 18-h culture of human pe- 
ripheral blood monocytes. IL-10 did not affect CDllb and 
CD14 expression (51), but, unlike observations in the mouse 
(52), profoundly inhibited class II MHC expression on human 
monocytes (51). Thus, it is possible that IL-10 suppresses 
IFN-3'  production in human PBMC by inhibiting IL-12 
production as well as by decreasing B7 or other CD28-1igand 
expression on some accessory  cells. Indeed, the ability of IL-12 
and anti-CD28 antibodies combined to induce IFN-3' produc- 
tion in PBMC was completely  resistant to IL-10. The syner- 
gistic effect of S.  aureus  and anti-CD28 was still inhibited 
by IL-10, as expected because S. aureus induces IFN-3' by trig- gering IL-12 production in PBMC, an IL-10-inhibitable  mech- 
anism. However, when IL-12 and anti-CD28 were added to- 
gether to S. aureus,  an almost complete resistance to IL-10 
was obtained. The partial inhibition by IL-10 in this case might 
be explained by its inhibition of other cofactors, e.g., TNF-ot 
and IL-13 (43-45). Because B7 is upregulated by IFN-3,, it 
is likely that this represents an amplifying feedback mecha- 
nism when IFN-y is induced by IL-12 in vitro or in vivo. 
Indeed, B7 expression on monocytes was upregulated after 
1-3 d of culture of PBMC with IL-12 or with the IL-12-in- 
ducing S. aureus; this effect was inhibited by anti-IFN-3' an- 
tibodies (not shown). 
The ability of monocyte-macrophages and B cells to present 
a surface counter-receptor and to secrete a soluble cytokine 
that cooperate with each other in a potent synergistic effect 
in inducing T cell activation, both in terms of proliferation 
and cytokine production, is likely to have physiologic sig- 
nificance in vivo during inflammation and immune response. 
Note that IFN-3' induced by IL-12 and B7 can enhance both 
secretion of IL-12 (53) and expression of B7 in monocytes 
(54), thus providing a double positive feedback loop. T cells 
activated by the B7/CD28  interaction and IL-12 also pro- 
duce GM-CSF and TNF-ot, which may also participate in 
macrophage activation and enhanced production of IL-12 
(Kubin, M.,  and G. Trinchieri, unpublished observations). 
This effect is likely to amplify both phagocytic cell and T 
cell activation, e.g., in bacteria-induced inflammation, until 
negative feedback mechanisms mediated by IL-10 and pos- 
sibly by IL-4, TGF-3,  and other pharmacologic mediators 
interrupt this amplifying circle. Because T cell activation medi- 
ated by B7 and IL-12 is at least in part independent of IL-2 
production, these mechanisms may represent an early, non- 
specific response to IL-12-inducing situations, e.g., bacterial 
or parasitic infection. Although activation of naive T  cells 
by B7 and IL-12 may not be, by itself, a sufficient physiolog- 
ical stimulus for T cell proliferation and even for IFN-3' produc- 
tion, a proportion of preactivated or memory T  cells able 
to respond to these stimuli, is probably present within cir- 
culating T cells. Furthermore, stimulation of  TCR by bacterial- 
derived superantigens (55) or other stimuli, possibly activating 
alternative stimulation pathways such as CD2 (26) or CD5 
(56),  may render naive T  cells responsive to B7 and IL-12 
stimulation for both early cytokine production and, eventu- 
ally, proliferation. This response could represent a first line 
of defense against infections, and also, depending on the pre- 
dominant cytokine pattern induced, affect development of 
antigen-specific  CD4 + and CD8 + cells. An early nonspecific 
ability to produce IFN-3~ and other phagocytic cell-activating 
cytokines has usually been attributed to NK cells rather than 
to T  cells (14,  57).  However, our in vitro results strongly 
suggest that in the presence of IL-12 and B7 expression on 
accessory T  cells,  T  cells  are likely to participate in these 
nonantigen-specific mechanisms. The participation of T cells 
may be dependent on and follow NK cell activation and 
production of IFN-'y; our data both in human and mouse 
have indeed shown a possible requirement for NK cells in 
the IL-12-induced differentiation of Thl  cells (7,  58). 
In a parallel study (37), we demonstrated a similar syner- 
gistic effect of B7 and IL-12 on proliferation and cytokine 
production in murine Thl clones; the ability of splenic APCs 
and antigen to induce proliferation and IFN-3' production 
in Thl clones was shown to depend on B7 expression on 
the APC and on IL-12 secretion. Preliminary results (Kubin, 
M., F. Gerosa, and G. Trinchieri, unpublished observation) 
show that human CD28 + T cell clones can also be activated 
synergistically  by anti-CD28 and IL-12, provided that respon- 
siveness to IL-12 in the clones is induced by PHA, similar 
to the requirement for antigen activation in the murine clones. 
It is therefore likely that the synergistic effect between B7 
and IL-12 is important for the activation of differentiation 
of quiescent T cells as well as for the maintained activation 
of the effector functions of established mature Thl clones. 
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